Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026
Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026
Company Deals

Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics

Fineline Cube Nov 22, 2022

Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...

Company Drug

Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China

Fineline Cube Nov 22, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing...

Company Drug

Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors

Fineline Cube Nov 22, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...

Company Drug

Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy

Fineline Cube Nov 22, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...

Company Drug

Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP

Fineline Cube Nov 22, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...

Company Deals

JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration

Fineline Cube Nov 22, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership...

Company Drug

Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications

Fineline Cube Nov 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...

Company Drug

Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic

Fineline Cube Nov 22, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...

Company Drug

Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong

Fineline Cube Nov 21, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...

Company Drug

IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD

Fineline Cube Nov 21, 2022

China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...

Company Deals Medical Device

ViVest Medical Raises Funds for Wearable Cardioverter Defibrillator Development

Fineline Cube Nov 21, 2022

Suzhou-based device maker ViVest Medical Technology Co., Ltd has reportedly raised “hundreds of millions” of...

Company Drug

Mabwell Receives Approval for Clinical Study of 9MW3011 in Polycythemia Vera

Fineline Cube Nov 21, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving approval to conduct a...

Policy / Regulatory

China’s CDE, HNMPA, and Bo’ao Lecheng Release Real-world Drug Research Measures

Fineline Cube Nov 21, 2022

The Center for Drug Evaluation (CDE), Hainan Medical Products Administration (HNMPA), and Bo’Ao Lecheng Medical...

Company Medical Device

Hotgen Biotech Receives FDA EUA for COVID-19 Antigen Home Test

Fineline Cube Nov 21, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving Emergency Use Authorization (EUA) from...

Company Deals

Wolters Kluwer Partners with China’s NCID to Advance Infectious Disease Diagnosis

Fineline Cube Nov 21, 2022

Holland-based information and software solutions provider Wolters Kluwer has announced a partnership with China’s National...

Policy / Regulatory

Jiangxi Healthcare Security Administration Launches New VBP Tender

Fineline Cube Nov 21, 2022

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement...

Company Deals

Fapon Biotech Partners with CR Pharma to Develop IVD Open Platform Ecosystem

Fineline Cube Nov 21, 2022

China-based biotech Fapon Biotech Inc. has announced a partnership with China Resources Pharmaceutical Commercial Group...

Company Drug

Henlius’ Serplulimab Phase III Study Approved in Spain for LS-SCLC

Fineline Cube Nov 21, 2022

China-based Shanghai Henlius Biotech (HKG: 2696) has announced that its global, multi-center Phase III clinical...

Company Drug

Hainan Poly Pharm Wins Finland Approval for Generic Cytovene-IV

Fineline Cube Nov 21, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Kangtai Biological Completes Phase III Clinical Data Analysis for COVID-19 Vaccine

Fineline Cube Nov 21, 2022

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the completion of the...

Posts pagination

1 … 627 628 629 … 695

Recent updates

  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
  • Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
  • Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
  • China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.